SCHEMBL1602933

SCHEMBL1602933

[2H]C1=CC2=CC3=NC(=CC4=NC(=CC5=NC(=CC1=N2)C=C5)C=C4)C=C3.[Sb]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1603263 0.95 — —
SCHEMBL1603958 0.95 — —
SCHEMBL1603253 0.95 — —
SCHEMBL1603317 0.95 — —
Hydrochloric Acid SCHEMBL6227562 0.93 — —
SCHEMBL466965 0.79 — —
Hydrochloric Acid SCHEMBL5165812 0.79 — —
SCHEMBL180000 0.79 — —
SCHEMBL1484247 0.64 — —
SCHEMBL4393759 0.62 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078220-B2 High-purity large-scale preparation of stannsoporfin Mallinckrodt Hospital Products IP Limited (IE) 2021-08-03 — — US disclosed
US-20200255458-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN MALLINCKRODT LLC 2020-08-13 — — US disclosed
US-10662209-B2 High-purity large-scale preparation of stannsoporfin Mallinckrodt Hospital Products IP Limited (IE) 2020-05-26 — — US disclosed
US-20190202846-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN SpecGx LLC 2019-07-04 — — US disclosed
US-10273255-B2 High-purity large-scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORPORATION (US) 2019-04-30 — — US disclosed
CN-104116745-B composition comprising stannsoporfin 婴儿护理药品公司 2018-07-06 — — CN disclosed
US-20180134735-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN MALLINCKRODT LLC 2018-05-17 — — US disclosed
US-9902745-B2 High-purity large-scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORPORATION (US) 2018-02-27 — — US disclosed
US-20170073362-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN VTESSE LLC 2017-03-16 — — US disclosed
US-9517239-B2 High-purity large-scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORPORATION (US) 2016-12-13 — — US disclosed
US-20150051184-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN SUCAMPO PHARMA AMERICAS LLC 2015-02-19 — — US disclosed
CN-104116745-A Compositions comprising stannsoporfin INFACARE PHARMACEUTICAL CORP 2014-10-29 — — CN disclosed
US-8835416-B2 High-purity large-scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORPORATION (US) 2014-09-16 — — US disclosed
US-20140005380-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN INFACARE PHARMACEUTICAL CORPORATION (US) 2014-01-02 — — US disclosed
US-8530458-B2 High-purity large-scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORPORATION (US) 2013-09-10 — — US disclosed
EP-2384756-A2 High-purity large-scale preparation of stannsoporfin InfaCare Pharmaceutical Corporation (US) 2011-11-09 — — EP disclosed
US-7960371-B2 reduction of hemin with hydrogenation catalysts, in the presence of hydrogen, then heating to remove iron and form mesoporphyrin, and reacting with tin oxide top form pure tin mesoporphyrin; inhibitor of heme oxygenase, used in the treatment of infant jaundice or hyperbilirubinemia; liver disorders INFACARE PHARMACEUTICAL CORPORATION (US) 2011-06-14 — — US disclosed
US-20110082292-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN OCERA THERAPEUTICS LLC 2011-04-07 — — US disclosed
CN-101573122-A High purity large scale preparation of stannsoporfin INFACARE PHARMACEUTICAL CORP (US) 2009-11-04 — — CN disclosed
US-20080125585-A1 HIGH-PURITY LARGE-SCALE PREPARATION OF STANNSOPORFIN STRATATECH CORPORATION 2008-05-29 — — US disclosed
Send feedback